To include your compound in the COVID-19 Resource Center, submit it here.

Delayed expectations for China’s patent reform

Patent law amendments may not be among the National People’s Congress’ priorities

Four months after China signed a “Phase One” trade deal with the U.S., patent law amendments may not be among the priorities of the National People’s Congress, leaving it unclear when expected pharmaceutical patent protections could materialize.

China has long discussed IP reforms, including a proposed amendment to its patent law that would protect innovative biopharmaceutical companies; however, concrete changes have not quickly followed.

In January 2019, the National People’s Congress (NPC) published a

Read the full 726 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE